|
|
Volumn 37, Issue 16, 2001, Pages 1965-1969
|
|
Translational research in clinical trials: The only way forward
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BETA 2 MICROGLOBULIN;
DEXAMETHASONE;
HEMOGLOBIN;
PROSTATE SPECIFIC ANTIGEN;
PROTEIN;
RITUXIMAB;
THALIDOMIDE;
ANTINEOPLASTIC ACTIVITY;
BONE MARROW SUPPRESSION;
CANCER THERAPY;
CELL PROLIFERATION;
CHEMOTHERAPY;
CLINICAL PRACTICE;
CLINICAL TRIAL;
DRUG ACTIVITY;
DRUG BIOAVAILABILITY;
DRUG BLOOD LEVEL;
DRUG EFFECT;
DRUG EFFICACY;
DRUG INDUCED DISEASE;
DRUG MECHANISM;
DRUG RESEARCH;
DRUG SCREENING;
DRUG SYNTHESIS;
DRUG TARGETING;
DRUG TOLERANCE;
HEMOGLOBIN DETERMINATION;
HUMAN;
MYELOMA;
NOTE;
PLASMACYTOMA;
PRIORITY JOURNAL;
PROSTATE CANCER;
QUALITY OF LIFE;
TREATMENT OUTCOME;
WALDENSTROEM MACROGLOBULINEMIA;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS;
DRUGS, INVESTIGATIONAL;
HUMANS;
NEOPLASMS;
|
|
EID: 0034773984
PISSN: 09598049
EISSN: None
Source Type: Journal
DOI: 10.1016/S0959-8049(01)00311-2 Document Type: Note |
|
Times cited : (5)
|
|
References (0)
|